MedTrace Logo

Evaluating the Dietary Supplement Anatabloc in Thyroid Health-ASAP (Antabloc Supplementation Autoimmune Prevention)

NCT01551498 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 165

Last updated 2015-11-02

No results posted yet for this study

Summary

This is a study to evaluate the safety, tolerability, and potential effects of Anatabloc dietary supplementation on antithyroid autoantibodies, thyroid structure, and thyroid function in subjects with autoimmune thyroiditis.

Conditions

  • Thyroiditis, Autoimmune

Interventions

DIETARY_SUPPLEMENT

Anatabloc Supplement

Product, as mint-flavored lozenges (3 mg anatabine per lozenge), to be taken 3 times each day

DIETARY_SUPPLEMENT

Placebo

Placebo, as mint flavored lozenges, to be taken 3 times each day

Sponsors & Collaborators

  • Rock Creek Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Maria Varga, MD · Star Scientific, Inc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2013-01-31
Completion
2013-02-28

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01551498 on ClinicalTrials.gov